Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | DGKA | P23743 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10014001 | 0.88 | HDAC6 (0.37) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL754509 | 0.86 | ADRA2A (0.42) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL18885533 | 0.84 | DGKA (0.35) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL12914653 | 0.82 | ADRA2A (0.38) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL21202243 | 0.81 | HTR2C (0.40) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL21202241 | 0.80 | HTR2C (0.42) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL25762064 | 0.80 | ADRA2A (0.39) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL14435883 | 0.80 | ADRA2A (0.39) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL25792122 | 0.78 | DGKA (0.39) | ADRA2AADRA1AMAPTBLMDGKA | |
| SCHEMBL14286296 | 0.78 | DGKA (0.42) | ADRA2AADRA1AMAPTBLMDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145126-A1 | ACRYLIC ACID PRODUCTION METHODS | NOVOMER, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20160016876-A1 | ACRYLIC ACID PRODUCTION METHODS | NOVOMER, INC. | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145126-A1 | ACRYLIC ACID PRODUCTION METHODS | ASS1, COASY, GGPS1 | ADRA2A 3999/4885ADRA1A 3628/4885MAPT 2462/4885 |
| US-20160016876-A1 | ACRYLIC ACID PRODUCTION METHODS | ASS1, COASY, GGPS1 | ADRA2A 3999/4885ADRA1A 3628/4885MAPT 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.